This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PHG vs. GRMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PHG vs. GRMN: Which Stock Is the Better Value Option?
Philips (PHG) Q1 Earnings Up on Solid Sales, China Growth
by Aniruddha Ganguly
Philips' (PHG) first-quarter 2019 results benefit from higher sales from Personal Health and Diagnosis & Treatment businesses.
Trimble's Tekla PowerFab Expands Steel Fabrication Portfolio
by Zacks Equity Research
Trimble (TRMB) rolls out a steel fabrication software solution - Tekla PowerFab - that offers real-time information to all project parties.
Scientific Games (SGMS) Q4 Earnings & Revenues Rise Y/Y
by Zacks Equity Research
Scientific Games (SGMS) fourth-quarter 2018 results benefit from robust performance of Lottery and Social segment but higher restructuring expenses hurt.
PHG or GRMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PHG vs. GRMN: Which Stock Is the Better Value Option?
Trade Desk (TTD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Trade Desk's (TTD) fourth-quarter 2018 results benefit from growth in CTV, strong customer retention and expanding international presence.
PHG or GRMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PHG vs. GRMN: Which Stock Is the Better Value Option?
New Strong Buy Stocks for February 6th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
Top Stock Reports for Pfizer, Biogen & Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Biogen (BIIB) and Schwab (SCHW).
Philips (PHG) Expands Personal Health Portfolio at CES 2019
by Zacks Equity Research
Philips' (PHG) new offerings at CES 2019 include sleep, oral and personal care solutions.
Koninklijke Philips' (PHG) Q3 Sales Up Y/Y, Earnings Down
by Zacks Equity Research
Koninklijke Philips' (PHG) third-quarter 2018 earnings benefits from the strong growth in Diagnosis & Treatment segment.
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA)
Philips Evolves as a Healthcare Company, Tariffs a Concern
by Zacks Equity Research
Koninklijke Philips (PHG) is gaining solid momentum as it further penetrates the healthcare market.
DKILY vs. PHG: Which Stock Is the Better Value Option?
by Zacks Equity Research
DKILY vs. PHG: Which Stock Is the Better Value Option?
Koninklijke Philips' (PHG) Q2 Earnings Up Y/Y, Sales Flat
by Zacks Equity Research
Koninklijke Philips' (PHG) second-quarter results benefit from robust performance in the Diagnosis & Treatment business.
Stock Market News For Jul 2, 2018
by Zacks Equity Research
Markets closed higher on Friday, the last trading session of the first half of the year, as energy stocks rallied.
LabCorp, Philips Tie Up to Advance in Digital Pathology
by Zacks Equity Research
Through the latest collaboration, LabCorp (LH) aims at strengthening its hold inthe high potential digital pathology market.
PHG vs. TRMB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PHG vs. TRMB: Which Stock Is the Better Value Option?
Philips EPD Buyout to Expand Image-Guided Therapy Portfolio
by Zacks Equity Research
Koninklijke Philips (PHG) is set to buy cardiac imaging and navigation system provider EPD solutions.
Philips (PHG) Reports Q1 Earnings, Comparable Order Intake Up
by Zacks Equity Research
Phillips' (PHG) first-quarter 2018 results benefit from its Diagnosis & Treatment businesses on the back of growth in Ultrasound, Diagnostic Imaging and Image-Guided Therapy.
Philips' Dual Use DRF System Gets FDA Nod for Marketing
by Zacks Equity Research
Koninklijke Philips's (PHG) new Digital Radiography-Fluoroscopy system receives approval of the U.S. Food and Drug Administration for marketing.
Philips Collaborates on Program for Medication Adherence
by Zacks Equity Research
Philips (PHG) joins forces with Partners Connected Health and Triad HealthCare Network for high quality patient care with lower cost of medical non-adherence.
Philips' (PHG) IntelliVue Guardian Enhances Patient Outcomes
by Zacks Equity Research
Philips (PHG) announces that Saratoga Hospital has successfully improved patient safety and clinical outcomes with the integration of Philips' IntelliVue Guardian.